Cullinan Therapeutics, Inc. (CGEM)
After hours:
| Previous Close | 27.17 |
| Open | 27.30 |
| Bid | 26.49 x 100 |
| Ask | 26.59 x 400 |
| Day's Range | 26.25 - 28.19 |
| 52 Week Range | 7.64 - 30.19 |
| Volume | |
| Avg. Volume | 723,827 |
| Market Cap | 1.144B |
| Beta (5Y Monthly) | -0.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.69 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.14 |
GuruFocus.comInsider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
Jennifer Michaelson, Chief Scientific Officer at Cullinan Therapeutics Inc (NASDAQ:CGEM), sold 63,606 shares of the company on May 7, 2024.
GlobeNewswireCullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. “I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio,” sa
- GlobeNewswire
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619
